13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • E7080-G000-218

    Acronym: 

    E7080-G000-218

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase II Tumour Stream Kidney
    Age Range 18 years and older Cancer Stage All stages
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Kidney
    Trial Type Treatment
    Phase Phase II
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Kidney
    Cancer Stage All stages
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A randomized , double-blinded, phase II trial to assess safety and efficacy of levantinib at two different starting doses (18mg vs. 14mg QD) in combination with everolimus (5mg QD) in renal cell carcinoma following one prior VEGF-targeted treatment

    Lay Summary

    Sponsor / Cooperative group

    Eisai

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Ashford Cancer Centre Research Helen Daykin hdaykin@adelaidecancercentre.com.au 08 8292 2240 Recruiting